Diabetes and gastric cancer: The potential links

World Journal of Gastroenterology

Volumn 20, Issue 7, 2014, Pages 1701-1711

  Tseng, Chin Hsiao ^a   Tseng, Farn Hsuan ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Diabetes mellitus; Epidemiology; Gastric cancer; Literature review; Meta analysis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SOMATOMEDIN C RECEPTOR; SULFONYLUREA DERIVATIVE; SALT INTAKE;

ARTICLE; CLINICAL EVALUATION; COMORBIDITY; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; HELICOBACTER INFECTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LIFESTYLE; MORTALITY; OBESITY; OVERALL SURVIVAL; RISK FACTOR; SALT INTAKE; SMOKING; STOMACH CANCER; ASIAN CONTINENTAL ANCESTRY GROUP; COMPLICATION; DIABETES COMPLICATIONS; FEEDING BEHAVIOR; FEMALE; HELICOBACTER PYLORI; MALE; META ANALYSIS (TOPIC); METABOLISM; STOMACH NEOPLASMS;

ASIAN CONTINENTAL ANCESTRY GROUP; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FOOD HABITS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; META-ANALYSIS AS TOPIC; METFORMIN; RISK FACTORS; SODIUM CHLORIDE, DIETARY; STOMACH NEOPLASMS;

EID: 84894234054     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i7.1701     Document Type: Article

References (123)

1. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121: 856-862 [PMID: 17397032 DOI: 10.1002/ijc.22717]
2. Tseng CH, Chong CK, Tai TY. Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006. Diabetologia 2009; 52: 240-246 [PMID: 19018510 DOI: 10.1007/ s00125-008-1204-8]
3. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380 [PMID: 16527702 DOI: 10.1016/j.cgh.2005.12.007]
4. Tseng CH. Type 2 diabetes, smoking, insulin use and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan. Hepatol Int 2013; 7: 693-702 [DOI 10.1007/s12072-012-9405-0]
5. Ben Q, Cai Q, Li Z, Yuan Y, Ning X, Deng S, Wang K. The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Eur J Cancer 2011; 47: 248-254 [PMID: 20709528 DOI: 10.1016/j.ejca.2010.07.010]
6. Tseng CH. New-onset diabetes with a history of dyslipidemia predicts pancreatic cancer. Pancreas 2013; 42: 42-48 [PMID: 22750971 DOI: 10.1097/MPA.0b013e3182571ba9]
7. Tseng CH. Diabetes, insulin use, smoking, and pancreatic cancer mortality in Taiwan. Acta Diabetol 2013; 50: 879-886 [PMID: 23508375 DOI: 10.1007/s00592-013-0471-0]
8. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679-1687 [PMID: 16288121 DOI: 10.1093/jnci/dji375]
9. Tseng CH. Diabetes but not insulin is associated with higher colon cancer mortality. World J Gastroenterol 2012; 18: 4182-4190 [PMID: 22919252 DOI: 10.3748/wjg.v18.i31.4182]
10. Tseng CH. Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol 2012; 167: 409-416 [PMID: 22778198 DOI: 10.1530/ EJE-12-0369]
11. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007; 50: 1365-1374 [PMID: 17476474 DOI: 10.1007/ s00125-007-0681-5]
12. Saltzman BS, Doherty JA, Hill DA, Beresford SA, Voigt LF, Chen C, Weiss NS. Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. Am J Epidemiol 2008; 167: 607-614 [PMID: 18071194 DOI: 10.1093/aje/kwm333]
13. Larsson SC, Wolk A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 2011; 54: 1013-1018 [PMID: 21274512 DOI: 10.1007/ s00125-011-2051-6]
14. Tseng CH. Diabetes and non-Hodgkin's lymphoma: analyses of prevalence and annual incidence in 2005 using the National Health Insurance database in Taiwan. Ann Oncol 2012; 23: 153-158 [PMID: 21765043 DOI: 10.1093/annonc/mdr334]
15. Tseng CH. Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan. Metabolism 2012; 61: 1003-1009 [PMID: 22237115 DOI: 10.1016/j.metabol.2011.11.015]
16. Tseng CH. Insulin use and smoking jointly increase the risk of bladder cancer mortality in patients with type 2 diabetes. Clin Genitourin Cancer 2013; 11: 508-514 [PMID: 23791436 DOI: 10.1016/j.clgc.2013.04.019]
17. Tseng CH, Chong CK, Tseng CP, Chan TT. Age-related risk of mortality from bladder cancer in diabetic patients: a 12-year follow-up of a national cohort in Taiwan. Ann Med 2009; 41: 371-379 [PMID: 19191082 DOI: 10.1080/0785389090 2729778]
18. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011; 54: 2009-2015 [PMID: 21544514 DOI: 10.1007/ s00125-011-2171-z]
19. Tseng CH. Pioglitazone and bladder cancer: a populationbased study of Taiwanese. Diabetes Care 2012; 35: 278-280 [PMID: 22210574 DOI: 10.2337/dc11-1449]
20. Tseng CH. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a populationbased cohort study using the National Health Insurance in Taiwan. BMC Cancer 2013; 13: 7 [PMID: 23286275 DOI: 10.1186/1471-2407-13-7]
21. Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, Foti D, Chiefari E, Brunetti A. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res 2012; 2012: 789174 [PMID: 22701472 DOI: 10.1155/2012/789174]
22. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-1685 [PMID: 20587728 DOI: 10.2337/dc10-0666]
23. Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2012; 30: 368-402 [PMID: 23167631 DOI: 10.1080/10590501.20 12.735519]
24. Tseng CH. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? J Formos Med Assoc 2012; 111: 123-131 [PMID: 22423665 DOI: 10.1016/j.jfma.2011.10.003]
25. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300 [PMID: 20610543 DOI: 10.3322/caac.20073]
26. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
27. Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012; 4: 156-169 [PMID: 22844547 DOI: 10.4251/wjgo.v4.i7.156]
28. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044 [PMID: 16404738 DOI: 10.1002/ijc.21731]
29. Correa P, Piazuelo MB. Helicobacter pylori Infection and Gastric Adenocarcinoma. US Gastroenterol Hepatol Rev 2011; 7: 59-64 [PMID: 21857882]
30. Tseng CH. Diabetes conveys a higher risk of gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan. Gut 2011; 60: 774-779 [PMID: 21193459 DOI: 10.1136/gut.2010.226522]
31. Ikeda F, Doi Y, Yonemoto K, Ninomiya T, Kubo M, Shikata K, Hata J, Tanizaki Y, Matsumoto T, Iida M, Kiyohara Y. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology 2009; 136: 1234-1241 [PMID: 19236964 DOI: 10.1053/j.gastro.2008.12.045]
32. Gong Y, Yang YS, Zhang XM, Su M, Wang J, Han JD, Guo MZ. ABO blood type, diabetes and risk of gastrointestinal cancer in northern China. World J Gastroenterol 2012; 18: 563-569 [PMID: 22363124 DOI: 10.3748/wjg.v18.i6.563]
33. Ge Z, Ben Q, Qian J, Wang Y, Li Y. Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies. Eur J Gastroenterol Hepatol 2011; 23: 1127-1135 [PMID: 21934509 DOI: 10.1097/MEG.0b013e32834b8d73]
34. Marimuthu SP, Vijayaragavan P, Moysich KB, Jayaprakash V. Diabetes mellitus and gastric carcinoma: Is there an association? J Carcinog 2011; 10: 30 [PMID: 22190872 DOI: 10.4103/1477-3163.90481]
35. Tian T, Zhang LQ, Ma XH, Zhou JN, Shen J. Diabetes mellitus and incidence and mortality of gastric cancer: a metaanalysis. Exp Clin Endocrinol Diabetes 2012; 120: 217-223 [PMID: 22187293 DOI: 10.1055/s-0031-1297969]
36. Yoon JM, Son KY, Eom CS, Durrance D, Park SM. Preexisting diabetes mellitus increases the risk of gastric cancer: a meta-analysis. World J Gastroenterol 2013; 19: 936-945 [PMID: 23429469]
37. Lin SW, Freedman ND, Hollenbeck AR, Schatzkin A, Abnet CC. Prospective study of self-reported diabetes and risk of upper gastrointestinal cancers. Cancer Epidemiol Biomarkers Prev 2011; 20: 954-961 [PMID: 21415356 DOI: 10.1158/1055-9965.EPI-10-1244]
38. Cavaleiro-Pinto M, Peleteiro B, Lunet N, Barros H. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control 2011; 22: 375-387 [PMID: 21184266 DOI: 10.1007/s10552-010-9707-2]
39. Lanzino M, Morelli C, Garofalo C, Panno ML, Mauro L, Andò S, Sisci D. Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr Cancer Drug Targets 2008; 8: 597-610 [PMID: 18991569 DOI: 10.2174/15680 0908786241104]
40. Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, Nakachi K, Gustafsson JA, Hayashi S. Estrogen receptor beta is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol 2002; 128: 319-324 [PMID: 12073050 DOI: 10.1007/s00432-002-0336-3]
41. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M, Gustafsson JA. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82: 4258-4265 [PMID: 9398750 DOI: 10.1210/jc.82.12.4258]
42. Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, Wu XT. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer 2009; 45: 2867-2873 [PMID: 19427197 DOI: 10.1016/j.ejca.2009.04.019]
43. Tseng CH. Body composition as a risk factor for coronary artery disease in Chinese type 2 diabetic patients in Taiwan. Circ J 2003; 67: 479-484 [PMID: 12808262 DOI: 10.1253/circj. 67.479]
44. Tseng CH. Body mass index and blood pressure in adult type 2 diabetic patients in Taiwan. Circ J 2007; 71: 1749-1754 [PMID: 17965496 DOI: 10.1253/circj.71.1749]
45. Tseng CH, Chong CK, Tseng CP, Shau WY, Tai TY. Hypertension is the most important component of metabolic syndrome in the association with ischemic heart disease in Taiwanese type 2 diabetic patients. Circ J 2008; 72: 1419-1424 [PMID: 18724015 DOI: 10.1253/circj.CJ-08-0009]
46. Tseng CH. Obesity paradox: differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus. Atherosclerosis 2013; 226: 186-192 [PMID: 23040832 DOI: 10.1016/j.atherosclerosis.2012.09.004]
47. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928 [PMID: 19029956 DOI: 10.1038/nrc2536]
48. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-169 [PMID: 22337149 DOI: 10.1038/nrc3215]
49. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131: 3109S-3120S [PMID: 11694656]
50. Yi HK, Hwang PH, Yang DH, Kang CW, Lee DY. Expression of the insulin-like growth factors (IGFs) and the IGFbinding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer 2001; 37: 2257-2263 [PMID: 11677116 DOI: 10.1016/ S0959-8049(01)00269-6]
51. Lee DY, Yi HK, Hwang PH, Oh Y. Enhanced expression of insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells. Biochem Biophys Res Commun 2002; 294: 480-486 [PMID: 12051736. DOI: 10.1016/S0006-291X(02)00491-6]
52. Adachi Y, Li R, Yamamoto H, Min Y, Piao W, Wang Y, Imsumran A, Li H, Arimura Y, Lee CT, Imai K, Carbone DP, Shinomura Y. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin. Carcinogenesis 2009; 30: 1305-1313 [PMID: 19493905 DOI: 10.1093/carcin/bgp134]
53. Pavelić K, Kolak T, Kapitanović S, Radosević S, Spaventi S, Kruslin B, Pavelić J. Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/ IGF 2R). J Pathol 2003; 201: 430-438 [PMID: 14595755 DOI: 10.1002/path.1465]
54. Thompson MA, Cox AJ, Whitehead RH, Jonas HA. Autocrine regulation of human tumor cell proliferation by insulin-like growth factor II: an in-vitro model. Endocrinology 1990; 126: 3033-3042 [PMID: 1693565 DOI: 10.1210/ endo-126-6-3033]
55. Bi Y, Wang T, Xu M, Xu Y, Li M, Lu J, Zhu X, Ning G. Advanced research on risk factors of type 2 diabetes. Diabetes Metab Res Rev 2012; 28 Suppl 2: 32-39 [PMID: 23280864 DOI: 10.1002/dmrr.2352]
56. Zendehdel K, Nyrén O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003; 95: 1797-1800 [PMID: 14652242 DOI: 10.1093/jnci/djg105]
57. Swerdlow AJ, Laing SP, Qiao Z, Slater SD, Burden AC, Botha JL, Waugh NR, Morris AD, Gatling W, Gale EA, Patterson CC, Keen H. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 2005; 92: 2070-2075 [PMID: 15886700 DOI: 10.1038/ sj.bjc.6602611]
58. Yamagata H, Kiyohara Y, Nakamura S, Kubo M, Tanizaki Y, Matsumoto T, Tanaka K, Kato I, Shirota T, Iida M. Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. Diabetes Care 2005; 28: 789-794 [PMID: 15793174 DOI: 10.2337/diacare. 28.4.789]
59. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004; 47: 1661-1667 [PMID: 15480539 DOI: 10.1007/s00125-004-1507-3]
60. Chocarro-Calvo A, García-Martínez JM, Ardila-González S, De la Vieja A, García-Jiménez C. Glucose-induced β-catenin acetylation enhances Wnt signaling in cancer. Mol Cell 2013; 49: 474-486 [PMID: 23273980 DOI: 10.1016/ j.molcel.2012.11.022]
61. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, Sung JJ. Dysregulation of cellular signaling in gastric cancer. Cancer Lett 2010; 295: 144-153 [PMID: 20488613 DOI: 10.1016/ j.canlet.2010.04.025]
62. Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp (Warsz) 2013; 61: 119-125 [PMID: 23307037 DOI: 10.1007/s00005-012-0210-1]
63. Katoh M. Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer. Cancer Biol Ther 2007; 6: 832-839 [PMID: 17568183 DOI: 10.4161/cbt.6.6.4196]
64. Yoshizawa N, Yamaguchi H, Yamamoto M, Shimizu N, Furihata C, Tatematsu M, Seto Y, Kaminishi M. Gastric carcinogenesis by N-Methyl-N-nitrosourea is enhanced in db/db diabetic mice. Cancer Sci 2009; 100: 1180-1185 [PMID: 19432903. DOI: 10.1111/j.1349-7006.2009.01157.x]
65. Lorenzi M, Montisano DF, Toledo S, Barrieux A. High glucose induces DNA damage in cultured human endothelial cells. J Clin Invest 1986; 77: 322-325 [PMID: 3944257 DOI: 10.1172/JCI112295]
66. Mahdy RA, Nada WM. Evaluation of the role of vascular endothelial growth factor in diabetic retinopathy. Ophthalmic Res 2011; 45: 87-91 [PMID: 20720438 DOI: 10.1159/000317062]
67. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314 [PMID: 13298683 DOI: 10.1126/science.123.3191.309]
68. Shimizu H, Monden T, Matsumura M, Domeki N, Kasai K. Effects of twice-daily injections of premixed insulin analog on glycemic control in type 2 diabetic patients. Yonsei Med J 2010; 51: 845-849 [PMID: 20879049 DOI: 10.3349/ ymj.2010.51.6.845]
69. Yamagata H, Kiyohara Y, Aoyagi K, Kato I, Iwamoto H, Nakayama K, Shimizu H, Tanizaki Y, Arima H, Shinohara N, Kondo H, Matsumoto T, Fujishima M. Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population: the Hisayama study. Arch Intern Med 2000; 160: 1962-1968 [PMID: 10888970 DOI: 10.1001/ archinte.160.13.1962]
70. Obst B, Wagner S, Sewing KF, Beil W. Helicobacter pylori causes DNA damage in gastric epithelial cells. Carcinogenesis 2000; 21: 1111-1115 [PMID: 10836997 DOI: 10.1093/carcin/ 21.6.1111]
71. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009; 137: 1641-8. e1-2 [PMID: 19664631 DOI: 10.1053/ j.gastro.2009.07.060]
72. Gasbarrini A, Ojetti V, Pitocco D, Franceschi F, Candelli M, Torre ES, Gabrielli M, Cammarota G, Armuzzi A, Pola R, Pola P, Ghirlanda G, Gasbarrini G. Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999; 11: 713-716 [PMID: 10445788. DOI: 10.1097/00042737-199907000-00005]
73. Ojetti V, Pitocco D, Bartolozzi F, Danese S, Migneco A, Lupascu A, Pola P, Ghirlanda G, Gasbarrini G, Gasbarrini A. High rate of helicobacter pylori re-infection in patients affected by type 1 diabetes. Diabetes Care 2002; 25: 1485 [PMID: 12145262. DOI: 10.2337/diacare.25.8.1485]
74. Ojetti V, Migneco A, Silveri NG, Ghirlanda G, Gasbarrini G, Gasbarrini A. The role of H. pylori infection in diabetes. Curr Diabetes Rev 2005; 1: 343-347 [PMID: 18220610 DOI: 10.2174/ 157339905774574275]
75. Ojetti V, Migneco A, Nista EC, Gasbarrini G, Gasbarrini A, Pitocco D, Ghirlanda G. H pylori re-infection in type 1 diabetes: a 5 years follow-up. Dig Liver Dis 2007; 39: 286-287 [PMID: 17275424. DOI: 10.1016/j.dld.2006.11.008]
76. Ojetti V, Pellicano R, Fagoonee S, Migneco A, Berrutti M, Gasbarrini A. Helicobacter pylori infection and diabetes. Minerva Med 2010; 101: 115-119 [PMID: 20467410]
77. Daoud AK, Tayyar MA, Fouda IM, Harfeil NA. Effects of diabetes mellitus vs. in vitro hyperglycemia on select immune cell functions. J Immunotoxicol 2009; 6: 36-41 [PMID: 19519161 DOI: 10.1080/15476910802604564]
78. Bener A, Micallef R, Afifi M, Derbala M, Al-Mulla HM, Usmani MA. Association between type 2 diabetes mellitus and Helicobacter pylori infection. Turk J Gastroenterol 2007; 18: 225-229 [PMID: 18080918]
79. Hamed SA, Amine NF, Galal GM, Helal SR, Tag El-Din LM, Shawky OA, Ahmed EA, Abdel Rahman MS. Vascular risks and complications in diabetes mellitus: the role of helicobacter pylori infection. J Stroke Cerebrovasc Dis 2008; 17: 86-94 [PMID: 18346651 DOI: 10.1016/j.jstrokecerebrovasdis]
80. Demir M, Gokturk HS, Ozturk NA, Kulaksizoglu M, Serin E, Yilmaz U. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. Dig Dis Sci 2008; 53: 2646-2649 [PMID: 18320319 DOI: 10.1007/s10620-007-0185-7]
81. Ariizumi K, Koike T, Ohara S, Inomata Y, Abe Y, Iijima K, Imatani A, Oka T, Shimosegawa T. Incidence of reflux esophagitis and H pylori infection in diabetic patients. World J Gastroenterol 2008; 14: 3212-3217 [PMID: 18506928 DOI: 10.3748/wjg.14.3212]
82. Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol 2002; 97: 604-611 [PMID: 11922554 DOI: 10.1111/j.1572-0241.2002.05537.x]
83. Kim JH, Park HS, Ko SY, Hong SN, Sung IK, Shim CS, Song KH, Kim DL, Kim SK, Oh J. Diabetic factors associated with gastrointestinal symptoms in patients with type 2 diabetes. World J Gastroenterol 2010; 16: 1782-1787 [PMID: 20380013 DOI: 10.3748/wjg.v16.i14.1782]
84. Tseng CH. Diabetes, insulin use and Helicobacter pylori eradication: a retrospective cohort study. BMC Gastroenterol 2012; 12: 46 [PMID: 22571603 DOI: 10.1186/1471-230X-12-46]
85. Selinger C, Robinson A. Helicobacter pylori eradication in diabetic patients: still far off the treatment targets. South Med J 2010; 103: 975-976 [PMID: 20818306 DOI: 10.1097/ SMJ.0b013e3181ee7dce]
86. Demir M, Gokturk HS, Ozturk NA, Serin E, Yilmaz U. Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study. Am J Med Sci 2009; 338: 459-464 [PMID: 19884816 DOI: 10.1097/ MAJ.0b013e3181b5d3cf]
87. Demir M, Gokturk HS, Ozturk NA, Arslan H, Serin E, Yilmaz U. Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. South Med J 2009; 102: 1116-1120 [PMID: 19864973 DOI: 10.1097/SMJ.0b013e3181bca538]
88. Sargýn M, Uygur-Bayramicli O, Sargýn H, Orbay E, Yavuzer D, Yayla A. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol 2003; 9: 1126-1128 [PMID: 12717872]
89. Aydemir S, Bayraktaroglu T, Sert M, Sokmen C, Atmaca H, Mungan G, Gun BD, Borazan A, Ustundag Y. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci 2005; 50: 2090-2093 [PMID: 16240220 DOI: 10.1007/s10620-005-3012-z]
90. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter 2009; 14: 144-150 [PMID: 19751440 DOI: 10.1111/j.1523-5378.2009.00705.x]
91. Aslan M, Horoz M, Nazligul Y, Bolukbas C, Bolukbas FF, Selek S, Celik H, Erel O. Insulin resistance in H pylori infection and its association with oxidative stress. World J Gastroenterol 2006; 12: 6865-6868 [PMID: 17106938]
92. Kaneko H, Konagaya T, Kusugami K. Helicobacter pylori and gut hormones. J Gastroenterol 2002; 37: 77-86 [PMID: 11871770. DOI: 10.1007/s005350200000]
93. Calam J. Helicobacter pylori modulation of gastric acid. Yale J Biol Med 1999; 72: 195-202 [PMID: 10780581]
94. Wilkin TJ. Is autoimmunity or insulin resistance the primary driver of type 1 diabetes? Curr Diab Rep 2013; 13: 651-656 [PMID: 24005814 DOI: 10.1007/s11892-013-0407-7]
95. Ge S, Feng X, Shen L, Wei Z, Zhu Q, Sun J. Association between Habitual Dietary Salt Intake and Risk of Gastric Cancer: A Systematic Review of Observational Studies. Gastroenterol Res Pract 2012; 2012: 808120 [PMID: 23125851 DOI: 10.1155/2012/808120]
96. Shikata K, Kiyohara Y, Kubo M, Yonemoto K, Ninomiya T, Shirota T, Tanizaki Y, Doi Y, Tanaka K, Oishi Y, Matsumoto T, Iida M. A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study. Int J Cancer 2006; 119: 196-201 [PMID: 16450397. DOI: 10.1002/ijc.21822]
97. Wang XQ, Terry PD, Yan H. Review of salt consumption and stomach cancer risk: epidemiological and biological evidence. World J Gastroenterol 2009; 15: 2204-2213 [PMID: 19437559. DOI: 10.3748/wjg.15.2204]
98. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007; 10: 75-83 [PMID: 17577615 DOI: 10.1007/s10120-007-0420-0]
99. Tsugane S. Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence. Cancer Sci 2005; 96: 1-6 [PMID: 15649247. DOI: 10.1111/j.1349-7006.2005.00006.x]
100. Zhong C, Li KN, Bi JW, Wang BC. Sodium intake, salt taste and gastric cancer risk according to Helicobacter pylori infection, smoking, histological type and tumor site in China. Asian Pac J Cancer Prev 2012; 13: 2481-2484 [PMID: 22938408 DOI: 10.7314/APJCP.2012.13.6.2481]
101. Peleteiro B, Lopes C, Figueiredo C, Lunet N. Salt intake and gastric cancer risk according to Helicobacter pylori infection, smoking, tumour site and histological type. Br J Cancer 2011; 104: 198-207 [PMID: 21081930 DOI: 10.1038/sj.bjc.6605993]
102. Gaddy JA, Radin JN, Loh JT, Zhang F, Washington MK, Peek RM, Algood HM, Cover TL. High dietary salt intake exacerbates Helicobacter pylori-induced gastric carcinogenesis. Infect Immun 2013; 81: 2258-2267 [PMID: 23569116 DOI: 10.1128/IAI.01271-12]
103. Breslin PA. An evolutionary perspective on food and human taste. Curr Biol 2013; 23: R409-R418 [PMID: 23660364 DOI: 10.1016/j.cub.2013.04.010]
104. Bajaj S, Prasad S, Gupta A, Singh VB. Oral manifestations in type-2 diabetes and related complications. Indian J Endocrinol Metab 2012; 16: 777-779 [PMID: 23087863 DOI: 10.4103/2230-8210.100673]
105. Gondivkar SM, Indurkar A, Degwekar S, Bhowate R. Evaluation of gustatory function in patients with diabetes mellitus type 2. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108: 876-880 [PMID: 19913725 DOI: 10.1016/ j.tripleo.2009.08.015]
106. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012; 2012: 413782 [PMID: 22719752 DOI: 10.1155/2012/413782]
107. Currie CJ, Poole CD, Gale EA. The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777 [PMID: 19572116 DOI: 10.1007/ s00125-009-1440-6]
108. Tseng CH. Diabetes, insulin use, and gastric cancer: a population-based analysis of the Taiwanese. J Clin Gastroenterol 2013; 47: e60-e64 [PMID: 23269314 DOI: 10.1097/MCG.0b013e31827245eb]
109. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-1754 [PMID: 19588120 DOI: 10.1007/s00125-009-1444-2]
110. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-1744 [PMID: 19565214. DOI: 10.1007/s00125-009-1418-4]
111. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699-1708 [PMID: 19597799 DOI: 10.1007/s00125-009-1441-5]
112. Sommerfeld MR, Müller G, Tschank G, Seipke G, Habermann P, Kurrle R, Tennagels N. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One 2010; 5: e9540 [PMID: 20209060 DOI: 10.1371/journal. pone.0009540]
113. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11: 20 [PMID: 21241523 DOI: 10.1186/1471-2407-11-20]
114. Tseng CH. Thyroid cancer risk is not increased in diabetic patients. PLoS One 2012; 7: e53096 [PMID: 23300866 DOI: 10.1371/journal.pone.0053096]
115. Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, Kobara H, Mori H, Himoto T, Okano K, Suzuki Y, Murao K, Masaki T. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012; 11: 549-560 [PMID: 22222629 DOI: 10.1158/1535-7163. MCT-11-0594]
116. Qian X, Li J, Ding J, Wang Z, Duan L, Hu G. Glibenclamide exerts an antitumor activity through reactive oxygen speciesc-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803. Biochem Pharmacol 2008; 76: 1705-1715 [PMID: 18840412 DOI: 10.1016/j.bcp.2008.09.009]
117. Zhang L, Hu JF, Li GQ, Xiao X, Su Q. Rosiglitazone reverses mitomycin C resistance in human gastric cancer cells. Am J Med Sci 2012; 343: 382-387 [PMID: 22052411 DOI: 10.1097/ MAJ.0b013e31822f3c63]
118. Leung WK, Bai AH, Chan VY, Yu J, Chan MW, To KF, Wu JR, Chan KK, Fu YG, Chan FK, Sung JJ. Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut 2004; 53: 331-338 [PMID: 14960510 DOI: 10.1136/gut.2003.021105]
119. Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 2013; 24: 1721-1730 [PMID: 23599253 DOI: 10.1093/annonc/ mdt150]
120. Ye X, Fu J, Yang Y, Gao Y, Liu L, Chen S. Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PLoS One 2013; 8: e71522 [PMID: 23936269 DOI: 10.1371/journal. pone.0071522]
121. Franzini L, Ardigò D, Cavalot F, Miccoli R, Rivellese AA, Trovati M, Zavaroni I, Vaccaro O. Women show worse control of type 2 diabetes and cardiovascular disease risk factors than men: results from the MIND. IT Study Group of the Italian Society of Diabetology. Nutr Metab Cardiovasc Dis 2013; 23: 235-241 [PMID: 22397873 DOI: 10.1016/ j.numecd.2011.12.003]
122. Fu AZ, Zhang Q, Davies MJ, Pentakota SR, Radican L, Seck T. Underutilization of statins in patients with type 2 diabetes in US clinical practice: a retrospective cohort study. Curr Med Res Opin 2011; 27: 1035-1040 [PMID: 21410303 DOI: 10.1185/ 03007995.2011.567257]
123. Tseng CH, Chong CK, Chan TT, Bai CH, You SL, Chiou HY, Su TC, Chen CJ. Optimal anthropometric factor cutoffs for hyperglycemia, hypertension and dyslipidemia for the Taiwanese population. Atherosclerosis 2010; 210: 585-589 [PMID: 20053403. DOI: 10.1016/j.atherosclerosis.2009.12.015]